F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comSyncom Formulations (India) Ltd is an established Indian pharmaceutical company with a strong presence in formulations, APIs, and contract manufacturing. With growing demand for affordable medicines, expanding exports, and improving operational efficiency, Syncom Formulations has gradually attracted investor attention in the small-cap pharma space.
In this article, we present a fresh, SEO-friendly analysis of Syncom Formulations (India) Ltd share price targets from 2026 to 2030, based on current market data, company fundamentals, and long-term pharmaceutical sector trends.
| Detail | Value |
|---|---|
| Open | ₹14.21 |
| Previous Close | ₹14.08 |
| Day’s High | ₹14.46 |
| Day’s Low | ₹14.13 |
| VWAP | ₹14.29 |
| 52-Week High | ₹23.49 |
| 52-Week Low | ₹14.02 |
| All-Time High | ₹27.90 |
| All-Time Low | ₹4.60 |
| Market Capitalization | ₹1,355 Cr |
| Volume | 8,55,476 |
| Value (Lacs) | 123.36 |
| 20D Avg Volume | 12,43,043 |
| 20D Avg Delivery (%) | 56.59% |
| Face Value | ₹1 |
| Book Value Per Share | ₹4.03 |
| Beta | 1.35 |
Syncom Formulations (India) Ltd operates across multiple pharmaceutical segments, including branded generics, APIs, and contract manufacturing services. The company caters to both domestic and export markets, focusing on affordable and essential medicines.
With India strengthening its position as a global pharmaceutical manufacturing hub, companies like Syncom Formulations stand to benefit from rising healthcare demand, export opportunities, and government support for the pharma sector.
Diversified product portfolio across therapeutic segments
Presence in both domestic and export markets
Focus on affordable generic medicines
Improving operational scale and manufacturing capabilities
Consistent retail participation and trading liquidity
India’s pharmaceutical sector continues to grow due to:
Rising healthcare awareness and chronic disease prevalence
Expansion of generic drug demand globally
Cost advantages in Indian pharma manufacturing
Small and mid-cap pharma companies may benefit from contract manufacturing opportunities and increasing demand for cost-effective formulations.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 50.57% |
| Retail & Others | 49.33% |
| Foreign Institutions | 0.10% |
A balanced promoter stake indicates management commitment, while high retail participation reflects growing investor interest in the stock.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2026 | 22 | 26 |
| 2027 | 27 | 32 |
| 2028 | 33 | 38 |
| 2029 | 40 | 46 |
| 2030 | 48 | 55 |
These projections consider revenue growth, sector expansion, improved margins, and broader market sentiment toward small-cap pharma stocks.
By 2026, improved capacity utilisation and steady demand for generics may support moderate growth.
Growth Drivers
Rising domestic healthcare demand
Stable generic medicine sales
Gradual improvement in profitability
Investment View: Suitable for high-risk investors seeking early-stage growth.
In 2027, expansion in exports and contract manufacturing could strengthen revenue visibility.
Growth Drivers
Export market penetration
Operational efficiency gains
Better cost management
Investment View: Positive outlook with improving fundamentals.
By 2028, consistent earnings growth may attract higher market valuations.
Growth Drivers
Broader product portfolio
Stronger distributor network
Rising demand for affordable medicines
Investment View: Suitable for investors with medium-to-long-term horizon.
As the pharma sector matures, Syncom Formulations may benefit from scale and market expansion.
Growth Drivers
Contract manufacturing opportunities
Export-driven revenue growth
Margin expansion
Investment View: Attractive for long-term investors comfortable with volatility.
By 2030, the company could emerge as a stronger mid-sized pharma player if growth execution remains consistent.
Growth Drivers
Long-term healthcare demand
Strengthened manufacturing base
Improved brand recognition
Investment View: High-risk, high-reward potential for long-term wealth creation.
Syncom Formulations (India) Ltd offers exposure to India’s growing pharmaceutical sector at a relatively small market size. While the stock carries higher volatility and execution risk, its long-term prospects may improve with consistent financial performance.
Growing pharma sector tailwinds
Affordable valuation compared to large pharma peers
Promoter commitment to business growth
High competition in generic medicines
Regulatory and compliance risks
Earnings volatility common in small-cap stocks
Syncom Formulations (India) Ltd represents a small-cap pharmaceutical opportunity with long-term growth potential tied to India’s expanding healthcare and export markets. While short-term fluctuations are expected, disciplined execution and sector growth could support higher valuations over time. Based on current trends, Syncom Formulations share price could range between ₹48 and ₹55 by 2030, making it suitable for investors with a higher risk appetite and long-term vision.
1. What is the current share price of Syncom Formulations (India) Ltd?
It trades near the levels mentioned in the latest market data and fluctuates daily.
2. What is the share price target for 2026?
The estimated range is ₹22 to ₹26.
3. Is Syncom Formulations (India) Ltd a good long-term investment?
It may be suitable for high-risk investors looking for exposure to small-cap pharma growth.
4. What is the projected share price target for 2030?
The expected range is ₹48 to ₹55.
5. What factors influence Syncom Formulations’ share price the most?
Revenue growth, profitability, regulatory compliance, export performance, and overall pharma sector trends.
Disclaimer: This article is for educational purposes only and does not constitute investment advice. Please consult a certified financial advisor before making any investment decisions.
Register & Login